ArticleBMC infectious diseases2026
Penicillin-nonsusceptible Streptococcus suis infections in humans: clinical characteristics and antimicrobial synergy testing.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAntimicrobial resistance in Streptococcus suis represents an increasing global health concern, particularly in Thailand, where human and swine infections remain common and severe.
methodsA descriptive study was conducted in northeastern Thailand from January 2020 to December 2024 to examine the association between clinical characteristics and penicillin susceptibility (susceptible, intermediate, resistant) among S. suis isolates. In vitro antibiotic interactions were assessed by checkerboard microdilution in 23 drug-resistant isolates.
resultsAmong 373 culture-confirmed S. suis cases, 161 isolates (43.2%) were analyzed for serotype and clonal complex (CC); serotype 2 predominated (95.0%), and CC1 was most common (30.4%). Most patients were male (70.2%), with a mean age of 56.9 ± 13.8 years and median illness duration of 3 days (IQR, 1–10). Bacteremia was the predominant clinical manifestation, followed by infective endocarditis (IE) and meningitis. Penicillin resistance increased from 7.1% in 2020 to 57.8% in 2024, whereas ceftriaxone resistance remained infrequent. Of 373 isolates, 62 were penicillin-susceptible, 225 intermediate, and 86 resistant. Meningitis was more frequently observed in penicillin-susceptible infections, whereas IE predominated in penicillin-nonsusceptible infections (P < 0.001). The overall case fatality rate was 28.4% (95% CI, 23.8–33.3) and did not differ by penicillin susceptibility group (P = 0.710). In vitro synergism was most frequently observed for ampicillin–ceftriaxone (39.1%) and penicillin–ceftriaxone (21.7%), whereas gentamicin combinations were mostly indifferent.
conclusionPenicillin-nonsusceptible S. suis was frequently identified among infections in northeastern Thailand. In vitro synergistic activity was observed for the ampicillin–ceftriaxone combination in a subset of isolates, warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.